52-Week Performance Chart

Powered by FactSet Research Systems Inc

No DR Events are available.

No DR Events are available.

Data provided by Thomson Reuters

Institutional Ownership

TOP INSTITUTIONAL HOLDERS POSITION
AllianceBernstein LP 14,725,158
Orbis Investment Management Ltd. 5,710,741
Citadel Advisors LLC 4,344,306
TOP MUTUAL FUND HOLDERS POSITION
AllianceBernstein (Japan) AB US Large Cap Growth Equity Mother 5,493,337
AB Large Cap Growth Fund 4,186,047
iShares Biotechnology ETF 2,903,260

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol GMXAY
CUSIP 372303206
DR Venue OTC
DR ISIN US3723032062
Ratio DR:ORD 2:1
Underlying ISIN DK0010272202
Country Denmark
Effective Date May 31, 2013
Depositary DB (Sponsored)
Industry Pharma. & Biotech.
Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. The Company's proprietary pipeline, includes bispecific T-cell engagers, immune checkpoint modulators, effector function improved antibodies and antibody-drug conjugates. The Company has seven product candidates in clinical development: tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014) and DuoBody-CD3xB7H4 (GEN1047). The Company's portfolio also includes four antibody technology platforms: DuoBody, HexaBody, DuoHexaBody, and HexElect.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Apr.25 21.15 32,813,744 1,562,559
Mar.25 19.58 31,861,569 1,517,218
Feb.25 22.68 26,234,144 1,380,744

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE